Literature DB >> 8983686

Pulmonary balloon valvuloplasty in the palliation of complex cyanotic congenital heart disease.

O Stümper1, J F Piéchaud, P Bonhoeffer, D Bonnet, Y Aggoun, D Sidi, J Kachaner.   

Abstract

OBJECTIVE: To assess the value of pulmonary balloon valvuloplasty in the interim palliation of complex congenital heart disease and pulmonary stenosis in children, who often require numerous palliative operations before definitive surgical repair.
METHODS: Evaluation of pulmonary balloon valvuloplasty procedures performed over a five year period in 18 patients (age 8 days--29 years; mean 5.5 years) with complex cyanotic congenital heart disease.
RESULTS: After pulmonary balloon valvuloplasty oxygen saturation increased from a mean (SD) of 69 (7.5)% to 83 (7.0)% (P < 0.001). Mean pulmonary artery pressure increased from a mean (SD) of 11.3 (3.8) mm Hg to 15.7 (3.9) mm Hg (P < 0.001). Transient complete atrioventricular block occurred in one patient. No other complications were encountered. In 5 patients (28%) there was an inadequate improvement in cyanosis compared with pre-procedure values (72 (4.7)% v 66 (8.1)%). Reasons for failure were increasing infundibular stenosis in three and inadequate mixing in one child. In 13 patients (72%) pulmonary balloon valvuloplasty gave adequate interim palliation over a mean follow up of 1.1 (1.3) years. Oxygen saturation was 81 (5.6)% at last follow up compared with 70 (7.3)% before pulmonary balloon valvuloplasty (P < 0.001).
CONCLUSION: Pulmonary balloon valvuloplasty is a safe and effective technique in the palliation of patients with complex cyanotic congenital heart disease associated with pulmonary valve stenosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983686      PMCID: PMC484551          DOI: 10.1136/hrt.76.4.363

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Balloon pulmonary valvotomy: palliation for cyanotic heart disease.

Authors:  M M Boucek; H E Webster; G S Orsmond; H D Ruttenberg
Journal:  Am Heart J       Date:  1988-02       Impact factor: 4.749

2.  Enhancing minority participation in research. The NHLBI experience.

Authors:  C Lenfant
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

3.  Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary-valve stenosis.

Authors:  J S Kan; R I White; S E Mitchell; T J Gardner
Journal:  N Engl J Med       Date:  1982-08-26       Impact factor: 91.245

4.  Percutaneous transluminal balloon valvuloplasty of congenital pulmonary valve stenosis, with a special report on infants and neonates.

Authors:  C Rey; P Marache; C Francart; C Dupuis
Journal:  J Am Coll Cardiol       Date:  1988-04       Impact factor: 24.094

5.  Balloon dilatation of the pulmonary valve in the first year of life in patients with tetralogy of Fallot: a preliminary study.

Authors:  S A Qureshi; C R Kirk; R K Lamb; R Arnold; J L Wilkinson
Journal:  Br Heart J       Date:  1988-09

6.  Independent predictors of long-term results after balloon pulmonary valvuloplasty. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators.

Authors:  B W McCrindle
Journal:  Circulation       Date:  1994-04       Impact factor: 29.690

7.  Experience with the modified Blalock-Taussig operation using polytetrafluoroethylene (Impra) grafts.

Authors:  P H Kay; A Capuani; R Franks; C Lincoln
Journal:  Br Heart J       Date:  1983-04

8.  [Palliative treatment of tetralogy of Fallot by percutaneous dilatation of the right ventricular outflow tract. 40 cases].

Authors:  J F Piéchaud; A B Delogu; L Iserin; Y Aggoun; L Cohen; D Sidi; J Kachaner
Journal:  Arch Mal Coeur Vaiss       Date:  1994-05

9.  Early balloon dilatation of the pulmonary valve in infants with tetralogy of Fallot. Risks and benefits.

Authors:  T Sluysmans; B Neven; J Rubay; J Lintermans; C Ovaert; J Mucumbitsi; P Shango; M Stijns; A Vliers
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

10.  Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia.

Authors:  G T Stavri; I C Zachary; P A Baskerville; J F Martin; J D Erusalimsky
Journal:  Circulation       Date:  1995-07-01       Impact factor: 29.690

  10 in total
  3 in total

Review 1.  Interventional catheterisation. Opening up I: the ventricular outflow tracts and great arteries.

Authors:  J L Gibbs
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

Review 2.  Non surgical treatment in congenital heart disease.

Authors:  S Radhakrishnan; S Shrivastava
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

Review 3.  [Interventions in congenital heart disease and their sequelae in adults].

Authors:  A A Schmaltz; U Neudorf; S Sack; O Galal
Journal:  Herz       Date:  1999-06       Impact factor: 1.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.